What's in Yuhan Corporation's pipeline?

Yuhan Corporation has 12 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with Yuhan Corporation's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/yuhan-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Yuhan Corporation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yuhan Corporation pipeline: 8 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 0 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Monorova® Tab	Monorova® Tab	marketed
Rosuvamibe® Tab	Rosuvamibe® Tab	marketed
Aripezil® Tab.	Aripezil® Tab.	marketed
YMC026	YMC026	marketed	Other
Monorova	Monorova	marketed	Other
Duowell®	Duowell®	marketed
Anagre Cap.	Anagre Cap.	marketed
Rosuvamibe	Rosuvamibe	marketed	Other

Therapeutic area mix

Other · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Yuhan Corporation:

Cite this brief

Drug Landscape (2026). Yuhan Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yuhan-corporation. Accessed 2026-05-16.